201 studies found for:    Open Studies | "Leukemia, Myelogenous, Chronic, BCR-ABL Positive"
Show Display Options
Download search resultsDownload the search results for:
Open Studies | "Leukemia, Myelogenous, Chronic, BCR-ABL Positive" (201 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Unknown  Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan
Conditions: Leukemia, Myelogenous, Chronic, BCR-ABL Positive;   Myelogenous Leukemia, Chronic, Chronic Phase
Intervention:
2 Unknown  Interventional Study to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Conditions: Leukemia, Myelogenous, Chronic, BCR-ABL Positive;   Medication Adherence
Interventions: Behavioral: Adherence-encouraging interventions - Group meeting;   Behavioral: Adherence-encouraging interventions - Individual meetings;   Behavioral: Adherence-encouraging interventions - Monthly phone calls
3 Not yet recruiting Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous Leukemia
Condition: Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interventions: Drug: Pioglitazone;   Drug: imatinib mesylate
4 Recruiting Extension Study of IDEAL (Imatinib) for Chronic Myelgenous Leukemia (CML)
Condition: Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Intervention: Drug: IDEAL-E observation (investigators choice of imatinib, nilotinib, dasatinib, radotinib)
5 Recruiting A Study Comparing Ponatinib and Nilotinib in Patients With Chronic Myeloid Leukemia
Condition: Chronic Phase Chronic Myeloid Leukemia
Interventions: Drug: ponatinib 30 mg QD;   Drug: ponatinib 15 mg QD;   Drug: nilotinib 400 mg BID
6 Recruiting Therapy of Early Chronic Phase Chronic Myelogenous Leukemia (CML) With Dasatinib
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Dasatinib
7 Recruiting Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia
Conditions: Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Pioglitazone Hydrochloride;   Drug: Tyrosine Kinase Inhibitor (TKI)
8 Recruiting Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib
Condition: Chronic Myeloid Leukemia
Intervention: Behavioral: Dasatinib discontinuation
9 Recruiting Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response
Condition: Chronic Phase Chronic Myeloid Leukemia
Intervention: Drug: P1101
10 Recruiting Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Condition: Chronic Myelogenous Leukemia
Intervention: Other: Chart Review
11 Recruiting Front-line Nilotinib Treatment of BCR-ABL+ Chronic Myeloid Leukaemia in Chronic Phase
Conditions: Chronic Phase Philadelphia Positive;   BCR-ABL Positive;   Chronic Myeloid Leukaemia
Intervention:
12 Recruiting TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy and Tolerability. The TIKlet Study
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Imatinib/Nilotinib
13 Recruiting LEONIDAS: Quality of Life Study in Chronic Myeloid Leukemia Patients
Condition: Chronic Myeloid Leukemia
Intervention: Other: QoL Survey Booklet
14 Recruiting Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
Conditions: Chronic Phase Chronic Myeloid Leukemia;   Accelerated Phase Chronic Myeloid Leukemia;   Blastic Phase Chronic Myeloid Leukemia;   Philadelphia Positive Acute Lymphoblastic Leukemia;   Resistant to Tyrosine Kinase Inhibitor Therapy
Interventions: Drug: Nilotinib;   Drug: Ruxolitinib
15 Recruiting Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.
Condition: Philidelphia Positive Chronic Myeloid Leukaemia
Intervention: Drug: Nilotinib
16 Recruiting Observational Study in Adults With Imatinib-resistant/Intolerant Chronic Myeloid Leukemia Treated With Nilotinib
Condition: Chronic Myeloid Leukaemia
Intervention: Drug: Imatinib
17 Recruiting Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Nilotinib
18 Available Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008
Condition: Chronic Myeloid Leukemia
Intervention: Drug: bosutinib
19 Not yet recruiting Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib
Conditions: Chronic Myeloid Leukemia;   Chronic Phase;   Adults
Intervention: Drug: Ponatinib
20 Not yet recruiting Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia
Condition: Chronic Myeloid Leukemia
Intervention: Drug: BL-8040

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years